Angelique Whitehurst, PhD

Funded by Kay Yow Cancer Fund 2023 Final Four Research Award

One of the greatest challenges in cancer treatment is that response to standard treatment is frequently incomplete and causes many side effects. Current treatments are often ineffective because they function as a “one-size-fits-all” approach to a very personal disease. This lack of success is magnified in triple negative breast cancer (TNBC), which differs greatly between each individual. We have recently discovered a protein that is not expressed anywhere in females, except in TNBC tumors, where it is required for tumor growth. This protein is normally only found in male testes. Thus, this protein is a perfect target to inhibit tumor growth without impacting normal tissues. Here we will study the function of ZNF165 and determine how it promotes growth of tumors. Ultimately, this work could lead to a tailored approach for treating TNBC without harming the patient.

Location: Harold C. Simmons Comprehensive Cancer Center - Dallas, TX
Proposal: Genetic Dissection of Therapeutic Intervention Targets in Triple Negative Breast Cancer
Mailing List Mailing List
Close Mailing List